雷帕鸣对肾移植有效果吗？

(Rapamune), formerly known as rapamycin, is a lipophilic triene nitrogen-containing macrolide antibiotic compound produced by Streptomyces hygroscopieus isolated from soil samples of Easier Island in the Pacific by Vezina and others at the Ayerst Laboratory in Canada in 1975.

Rapamin needs to be taken orally once a day. Concomitant use with cyclosporine and corticosteroids is recommended. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day.

It was initially used as a low-toxic antifungal drug. In 1977, it was found to have immunosuppressive effects. In 1989, RAPA began to be tried out as a new drug to treat rejection of organ transplants. Judging from the effects of animal experiments and clinical applications, it is a new immunosuppressant with good efficacy, low toxicity, and no nephrotoxicity. Compared with cyclosporine, Rapamune oral solution has a smaller dose (only 2 to 3 mg taken each time), stronger anti-rejection effect, and fewer side effects.

Since its launch, Rapamune has quickly become a commonly used oral immunosuppressant for organ transplant recipients around the world (especially kidney transplants). Rapamune is a serine/threonine kinase regulated by phosphoinositide-3-kinase and an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a protein that controls many cellular processes, including angiogenesis and cell synthesis, making it a reasonable target for inhibiting severe vascular tumors. Recently, in multiple clinical research reports involving vascular malformations and refractory vascular tumors, Rapamune has been proven to have a significant effect in vascular and lymphoproliferative diseases.

The above is the therapeutic effect of Rapamin provided by our medical companion team. From this point of view, the effect is still very ideal.